- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.07. | ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture | ||
| 30.07. | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| 29.07. | South Korea emerges as 2025 licensing hub with 113% growth and billion-dollar deals | ||
| 29.07. | BMS and Bain Capital forge $300m immunology spinoff | ||
| 29.07. | US instils 15% tariff rate on EU for pharmaceutical products | ||
| 29.07. | Alfasigma sets stage for Jyseleca in axSpA after Phase III win | ||
| 29.07. | Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies | ||
| 29.07. | Sarepta allowed to continue US Elevidys shipments | ||
| 29.07. | Ascendis Pharma's Skytrofa gains FDA approval for growth hormone deficiency | ||
| 28.07. | HS market forecast to reach $7.8bn across 7MM by 2034 | ||
| 28.07. | Gilead wins positive European approval opinion for twice-yearly HIV injection | ||
| 28.07. | How linked data can unlock the full potential of healthcare research | ||
| 28.07. | Sanofi's Sarclisa gains EC approval for multiple myeloma treatment | ||
| 28.07. | Hengrui Pharma and GSK link across key therapeutic areas | ||
| 28.07. | Synthetic rescue: Insmed explores a new frontier in genetic therapeutics | ||
| 25.07. | Pharma braces for critical French drug pricing reforms pending CEPS's report | ||
| 25.07. | UK-India $4.8bn FTA poised to benefit medtech and pharma | ||
| 25.07. | CHMP rejects Elevidys in latest setback for Sarepta | ||
| 25.07. | Why the AI hype isn't the whole story: let's focus on the benefits | ||
| 25.07. | The promise and challenges of the Unified Study Definition Model (USDM) | ||
| 25.07. | Pfizer and 3SBio conclude licensing deal for SSGJ-707 | ||
| 25.07. | GSK's Blenrep combos approved for multiple myeloma in EU | ||
| 24.07. | Apnimed sets sights on sleep apnoea pill approval following Phase III win | ||
| 24.07. | Novo Nordisk defeated in Wegovy patent dispute by Viatris | ||
| 24.07. | Kling Bio and Sanofi link for antibodies and epitopes discovery |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .